PhRMA releases DTC comments

Share this article:
PhRMA's Office of Accountability released its second survey of comments received by companies regarding DTC ads, which showed concern among consumers and physicians about the clarity and creative choices of some ads.

PhRMA did not release the comments, but said most concerned the public health benefits of DTC ads and compliance with FDA regulations. Comments on the public health benefits of ads went both ways, with a number of negative comments concerning specific actors used in ads. Substantial numbers of commenters also expressed confusion about details of an ad or about risk information.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.